Lyra Therapeutics, Inc. Quarterly Income Tax Expense (Benefit) in USD from Q1 2023 to Q2 2024

Taxonomy & unit
us-gaap: USD
Description
Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.
Summary
Lyra Therapeutics, Inc. quarterly/annual Income Tax Expense (Benefit) history and growth rate from Q1 2023 to Q2 2024.
  • Lyra Therapeutics, Inc. Income Tax Expense (Benefit) for the quarter ending June 30, 2024 was $12K, unchanged year-over-year.
  • Lyra Therapeutics, Inc. Income Tax Expense (Benefit) for the twelve months ending June 30, 2024 was $59K.
  • Lyra Therapeutics, Inc. annual Income Tax Expense (Benefit) for 2023 was $59K, a 354% increase from 2022.
  • Lyra Therapeutics, Inc. annual Income Tax Expense (Benefit) for 2022 was $13K.
  • Lyra Therapeutics, Inc. annual Income Tax Expense (Benefit) for 2021 was $0.000.
Income Tax Expense (Benefit), Trailing 12 Months (USD)
Income Tax Expense (Benefit), Quarterly (USD)
Income Tax Expense (Benefit), YoY Quarterly Growth (%)
Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q2 2024 $59K $12K $0 0% Apr 1, 2024 Jun 30, 2024 10-Q 2024-08-14
Q1 2024 $59K $14K $0 0% Jan 1, 2024 Mar 31, 2024 10-Q 2024-04-30
Q4 2023 $59K $17K Oct 1, 2023 Dec 31, 2023 10-K 2024-03-22
Q3 2023 $16K Jul 1, 2023 Sep 30, 2023 10-Q 2023-11-07
Q2 2023 $12K Apr 1, 2023 Jun 30, 2023 10-Q 2024-08-14
Q1 2023 $14K Jan 1, 2023 Mar 31, 2023 10-Q 2024-04-30
* An asterisk sign (*) next to the value indicates that the value is likely invalid.